|Mr. Yoshihiko Hatanaka||Pres, CEO & Representative Director||1.69M||N/A||N/A|
|Mr. Chikashi Takeda||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Percival Barretto-Ko||Sr. VP of International Operations||N/A||N/A||N/A|
|Mr. Fumiaki Sakurai||Chief Admin. Officer & Chief Ethics & Compliance Officer||N/A||N/A||N/A|
|Ms. Linda Friedman J.D.||Gen. Counsel & VP||N/A||N/A||N/A|
Astellas Pharma Inc., a pharmaceutical company, manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy. In addition, the company offers Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. Further, the company provides Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, and degarelix for oncology indications. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Astellas Pharma Inc.’s ISS Governance QualityScore as of October 15, 2017 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 2; Compensation: 1.